Skip to content

Company intelligence

Beyond the price.
Inside the business.

Explore this page

VTRS — Viatris Inc.

NASDAQ · Utilities · Small Cap · Mkt cap $23.4B · Vol 10.38M

$20.45

▼ -1.92% today

Live · market · updated 10:07:35 PM

Day $20.41–$20.68 · 52w $10.15–$21.20

Research Viatris Inc. (NASDAQ: VTRS) using available valuation, profitability and leverage data. Check each figure's source and compare reporting periods before drawing conclusions. Missing provider data must not be treated as a reported company fact.

About Viatris Inc.

Listed company
Viatris Inc.
Exchange and ticker
NASDAQ stock directory · VTRS
Provider sector
Healthcare
Provider industry
Drug Manufacturers - Specialty & Generic

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Source: Yahoo Finance — Viatris Inc. company profileCompany website

Financial statements and reporting periods

Available ratios are snapshots. This page does not provide a complete historical quarterly-results, profit-and-loss, balance-sheet or shareholding series. Use company filings to verify reporting periods, accounting changes and trends.

DeepScreen verdict

Hold
48
48

Weighted 13-factor score / 100

Viatris Inc. scores 48/100 on the DeepScreen quality-and-value model. Growth is running near -0.3% with a PEG of 3.77, ROCE of 1.3% and debt/equity at 0.99x. Quality and price roughly offset each other; wait for a better entry or clearer growth.

Strengths

  • + P/E Ratio (TTM): 7.4x — cheap vs. earnings
  • + EV/EBITDA: 8.1x — low multiple
  • + Operating Leverage: 2.17x — good upside gearing
  • + P/S Ratio: 1.59x — modest sales multiple

Risks

  • − PEG Ratio: 3.77 — overvalued vs. growth
  • − ROE: -4.2% — weak
  • − ROCE: 1.3% — below cost of capital risk
  • − ROA: 2.9% — asset-heavy / inefficient

Vision & Utility score and Secret Tips badges is a DeepScreen Pro feature

Unlock from ₹50/week · ₹175/month · ₹1800/year

Unlock Pro

Target price, trim level & stop-loss is a DeepScreen Pro feature

Unlock from ₹50/week · ₹175/month · ₹1800/year

Unlock Pro

Why this score?

The 48/100 score is a weighted average of 13 fundamental factors. This panel shows which factor scores contribute most to the current model result.

Model explanation

Highest-scoring factors

P/E Ratio (TTM)100/100 · 1.0× weight

Cheap vs. earnings. Weighted contribution: 7.8 points.

EV/EBITDA100/100 · 1.2× weight

Low multiple. Weighted contribution: 9.4 points.

Operating Leverage98/100 · 0.6× weight

Good upside gearing. Weighted contribution: 4.6 points.

P/S Ratio95/100 · 0.7× weight

Modest sales multiple. Weighted contribution: 5.2 points.

Lowest-scoring factors

ROCE5/100 · 1.6× weight

Below cost of capital risk. Weighted contribution: 0.6 points.

ROE5/100 · 1.3× weight

Weak. Weighted contribution: 0.5 points.

PEG Ratio5/100 · 1.6× weight

Overvalued vs. growth. Weighted contribution: 0.6 points.

Payout Ratio10/100 · 0.5× weight

Red flag — paying out more than it earns. Weighted contribution: 0.4 points.

Factor scores are model outputs, not forecasts. A high or low factor score describes how that metric is treated by the DeepScreen rules; review the underlying value and its source before drawing a broader conclusion.

Live fundamentals snapshot

Current operating, capital-efficiency and cash-flow metrics using the latest available provider data.

Live where available
Updated 10:07:35 PM
Revenue growthLive
-0.3%

Provider-reported period-over-period growth

Earnings growthModeled
Unavailable

Provider-reported period-over-period growth

ROELive
-4.2%

Return on equity

ROCEModeled
1.3%

Return on capital employed

Net marginLive
-4.1%

Net income as a share of revenue

D/ELive
1.0x

Debt relative to shareholder equity

Free cash flowLive
$3.16B

127% of operating cash flow

Cash vs debtLive
$11.57B net debt

Cash $2.01B · Debt $13.58B

Provider periods can differ by field. Growth figures are presented as reported by the upstream provider; they are not reconstructed from an expensive historical time series.

Current research alerts

Threshold-based research checks from the latest available fundamentals. These are on-page signals, not push notifications or predictions.

Payout ratio exceeds 100%

The model sees a 960% payout ratio. Check dividend funding against earnings and free cash flow.

Cash conversion is currently solid

Free cash flow is 127% of operating cash flow in the latest provider snapshot.

Signals are intended to highlight questions for research, not replace company filings or independent review.

Closest peer competitors

Industry match: Drug Manufacturers - Specialty & Generic. Peers use the same regional market universe, same sector, provider-reported industry where available, and market-cap proximity.

Loading

Peer fundamentals are still loading. The comparison will populate automatically when comparable company data arrives.

DeepScreen Secret Tips, traps & X-Ray analysis is a DeepScreen Pro feature

Unlock from ₹50/week · ₹175/month · ₹1800/year

Unlock Pro

God's Eye forensics

Accounting quality and solvency screens. Anything that can't be computed from available filings data is left blank rather than estimated.

Piotroski F-Score

4/8

4

4 of 8 financial-health checks passed (1 checks need data this provider doesn't publish).

Altman Z-Score

Insufficient data

—

Needs total assets, operating profit and debt — not published for this listing yet.

Beneish (earnings quality)

High manipulation risk

-4.09

Accrual-quality check only: operating cash flow is -409% of reported net profit. Below 80% means profits aren't fully backed by cash.

Scores are free. The criteria-by-criteria breakdown — exactly which checks this company failed — is part of DeepScreen Pro.

Fundamental breakdown — core ratios are free · EV/Revenue, PEG, EV/EBITDA and LT D/E are Pro-only live via Yahoo Finance, updated 10:07:35 PM

P/E Ratio (TTM)

Modeled

7.4x

Cheap vs. earnings

Price divided by earnings per share: how much you pay today for ₹1/$1 of annual profit. Only compare within the same industry.

PEG Ratio

Live

Pro

Advanced ratio · DeepScreen Pro

Pro

P/S Ratio

Live

1.59x

Modest sales multiple

Price relative to revenue. Sales are much harder to accounting-fudge than earnings, so this is a trustworthy number — and it's often the only usable multiple for loss-making or early-stage companies where P/E doesn't exist. But revenue without margin means nothing on its own: always read it alongside net margin.

P/B Ratio

Live

1.71x

Reasonable

Price versus net asset value on the balance sheet. Most meaningful for banks, NBFCs and asset-heavy businesses (manufacturing, real estate) where book value closely tracks real worth.

EV/Revenue

Live

Pro

Advanced ratio · DeepScreen Pro

Pro

EV/EBITDA

Live

Pro

Advanced ratio · DeepScreen Pro

Pro

ROE

Live

-4.2%

Weak

Return on shareholder equity. High ROE is great — unless it is manufactured by heavy debt, so always read it next to ROA and D/E: high ROE with low ROA is the classic debt-trap pattern.

ROA

Live

2.9%

Asset-heavy / inefficient

Net Income / Total Assets — how efficiently the whole business converts its asset base into profit. Computed as ROE / (1 + D/E) when live data is unavailable. Only compare within the same industry: asset-light businesses (IT, services) will always show a structurally higher ROA than asset-heavy ones (steel, airlines, utilities) simply because they carry far less on the balance sheet to begin with, not because they're better run.

ROCE

Modeled

1.3%

Below cost of capital risk

Return on all capital employed (equity plus debt). The cleanest quality signal because debt cannot flatter it.

Debt / Equity

Live

0.99x

Manageable

Total liabilities divided by shareholders' equity — the broadest leverage measure. High leverage boosts ROE in good years and destroys it in bad ones.

LT Debt / Equity

Modeled

Pro

Advanced ratio · DeepScreen Pro

Pro

Payout Ratio

Live

960%

Red flag — paying out more than it earns

Share of profit paid out as dividend. Above 100% means the company is funding the dividend from debt or reserves, not profit — a genuine red flag, not just 'high'. 30–60% is the classic sustainable balance; well below that usually just means a growth company reinvesting rather than anything wrong.

Operating Leverage

Modeled

2.17x

Good upside gearing

How much profit jumps for each 1% of extra sales — driven by how much of the cost base is fixed (rent, salaries) versus variable (raw materials). It's a double-edged sword: high fixed-cost businesses (manufacturing, airlines, software) see profit jump disproportionately as sales grow, but the same fixed costs turn a small sales dip into an outsized loss. That's also why these businesses tend to lead in a bull market and get hit hardest first when demand turns down.

DCF & Graham intrinsic value calculators is a DeepScreen Pro feature

Unlock from ₹50/week · ₹175/month · ₹1800/year

Unlock Pro

Company financials

EPS (TTM)
$-0.53
Revenue (TTM)
$14.7B
Net margin
-4.13%
EBITDA margin
29.72%
Earnings growth
-0.3%
Dividend yield
0.02%
Payout ratio
960%
Debt / equity
0.99x

Figures use live Yahoo Finance data where available; any field Yahoo doesn't report falls back to the DeepScreen model.

VTRS live news

UPDATING

Loading live headlines…

Frequently asked questions about VTRS

How does DeepScreen analyze Viatris Inc.?
DeepScreen uses a 13-factor valuation and quality model. The methodology explains the inputs, weighting and limitations; model output is analytical research, not a personalized investment recommendation.
What is VTRS's P/E ratio?
A provider-backed P/E is currently unavailable. The defensible approach is to calculate or verify it from the latest price and reported trailing earnings rather than substitute a synthetic figure.
How should I assess Viatris Inc.'s profitability?
For Viatris Inc., the latest provider-backed snapshot shows the latest growth measure is -0.30%, net margin is -4.13%, ROE is -4.2%. Consistent profitability and healthy year-over-year growth should be confirmed over several reporting periods, with earnings reconciled to operating cash flow and one-off items removed from the analysis.
How much debt does Viatris Inc. have?
The latest provider-backed debt-to-equity ratio is 0.99x. Total debt is approximately $13.58B, while cash is approximately $2.01B. Assess leverage together with interest expense, maturities and operating cash flow.
Is VTRS a buy?
DeepScreen provides research tools rather than a personalized recommendation. A decision should consider business quality, valuation, balance-sheet risk, disclosures, liquidity and your own objectives and risk tolerance.
How does the company make money?
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. This describes the company's disclosed business activity; for exact segment revenue, geography and customer concentration, use the latest annual report.
What is the company's competitive advantage (economic moat)?
Viatris Inc.'s potential moat should be evaluated from observable business economics: scale or cost advantages, network effects, switching costs, brand strength, patents or licences, distribution advantages and barriers to entry. The strongest evidence is a durable combination of pricing power, stable/growing margins and returns on capital over many years; a high ROE or ROCE alone does not prove a moat.
Who are the main competitors, and how does the company differ from them?
DeepScreen's directory-based comparison candidates include APVO (Aptevo Therapeutics Inc.), MOS (Mosaic Company (The)), POR (Portland General Electric Co), CWCO (Consolidated Water Co. Ltd.), KN (Knowles Corporation). Sector labels and market-cap proximity can use inferred or modeled directory inputs; these candidates are not a verified list of direct competitors; the direct comparison should use products, customers, geography, margins, growth, returns on capital and valuation.
Are its products or services in long-term demand?
The provider classifies Viatris Inc. in Drug Manufacturers - Specialty & Generic. Long-term demand is supported when the underlying industry, customer base and product/service use remain durable over multiple years. For Viatris Inc., test that through multi-year revenue and customer trends, retention/repeat purchases where applicable, pricing power, capacity utilisation and the risk of substitution or technological disruption.
Who are its primary customers (individuals, businesses, or government)?
The provider's business profile describes Viatris Inc.'s activities as follows: Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Customer mix itself is not a stock-market ratio, so the primary customers should be confirmed from the company's segment, geographic and customer disclosures.
Is the company consistently profitable, and is its revenue growing year-over-year?
For Viatris Inc., the latest provider-backed snapshot shows the latest growth measure is -0.30%, net margin is -4.13%, ROE is -4.2%. Consistent profitability and healthy year-over-year growth should be confirmed over several reporting periods, with earnings reconciled to operating cash flow and one-off items removed from the analysis.
Does the company generate positive, healthy free cash flow?
The latest provider snapshot reports free cash flow of approximately $3.16B, with operating cash flow of about $2.49B. Whether that cash flow is healthy depends on persistence, conversion of profit to cash, capital expenditure needs and working-capital movements; inspect multiple periods rather than one TTM figure.
How high are the company's debt levels compared to its cash holdings and earnings?
The current snapshot shows D/E of 0.99x, debt of roughly $13.58B, cash of roughly $2.01B, implying net debt of about $11.57B. The full debt burden should be compared with EBITDA/EBIT, interest expense, maturities and recurring free cash flow.
How will the company finance its future growth or expansion projects?
Viatris Inc. currently has reported cash of about $2.01B and free cash flow of about $3.16B. Those internal resources can contribute to expansion, while additional funding can come from operating cash flow, debt, equity issuance, asset sales or project finance. The exact funding mix for a specific project must come from management's disclosed plans.
What is the company's historical Return on Equity (ROE) and Return on Capital Employed (ROCE)?
The latest snapshot reports ROE of -4.2%no current live ROCE. Historical quality should be judged from a multi-year series and by checking whether returns remain above the company's cost of capital through different business conditions.
Who are the promoters or top executives running the company, and what is their track record?
The current provider profile lists these senior executives: Mr. Scott Andrew Smith Ph.D. (CEO & Director); Mr. Andrew Enrietti (Chief Administrative & Transformation Officer); Dr. Corinne M. Le Goff M.B.A., Pharm.D. (Chief Commercial Officer); Mr. Paul B. Campbell (Interim CFO, Chief Accounting Officer & Corporate Controller); Mr. Ramkumar V. Rayapureddy (Chief Information Officer). Track record should be assessed through capital-allocation decisions, operating results, governance disclosures and execution against stated targets. For Indian companies, promoter identity and ownership should be checked against the latest exchange shareholding filing.
Is a high percentage of the promoter's stake pledged as collateral for loans?
Promoter pledge is a shareholding-disclosure item, not a normal valuation ratio. For an Indian company, check the latest exchange shareholding pattern and notes for pledged/encumbered promoter shares, and compare the percentage with prior quarters to identify changes. Do not infer pledge levels from debt-to-equity.
Does management have a transparent and honest history of communication with shareholders?
The strongest evidence is consistency between what management says and what later appears in reported results: guidance versus delivery, explanations for misses, treatment of related parties, restatements, capital allocation and disclosure of material risks. A multi-year record is needed; tone alone is not a reliable measure of transparency.
Is the current stock valuation (such as the P/E or P/S ratio) reasonable or overpriced?
A live provider-backed P/E is not available and P/S is 1.59x . These are descriptive multiples, not conclusions by themselves. A defensible valuation assessment compares the multiple with sustainable growth, margins, ROE/ROCE, balance-sheet risk, cyclicality and direct peers.
How does the company's valuation compare to its direct industry peers?
A practical peer set for Viatris Inc. starts with APVO (Aptevo Therapeutics Inc.), MOS (Mosaic Company (The)), POR (Portland General Electric Co), CWCO (Consolidated Water Co. Ltd.), KN (Knowles Corporation). Compare the same reporting-period P/E, P/S and positive EV/EBITDA only when EBITDA supports a meaningful multiple, then adjust for growth, margin quality, leverage and business mix; a lower positive multiple is not automatically cheaper on an economic-value basis.
What is the margin of safety if market conditions or the economy worsens?
Margin of safety is created by buying with a gap between conservative intrinsic value and market price, then stress-testing the downside case. The relevant stress tests are lower revenue/earnings growth, lower margins, higher funding costs, weaker working capital and a lower terminal valuation. There is no universal fixed percentage that applies to every company.
Does the company pay a reliable dividend, or does it aggressively buy back its own shares?
The latest provider-backed dividend yield is 0.0% and payout ratio is 960.00% . Dividend reliability should be checked across several years and against free cash flow, while buyback intensity should be verified from share-count changes, treasury-share activity and cash-flow statements. A one-year yield cannot establish a durable shareholder-distribution policy.

Stock research topics

Stocks, prices & forecasts

Review the scoring factors, underlying data and limitations before comparing companies.

Read the methodology